Tissue-agnostic cancer drug explained

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.^{[1] [2] [3]} Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.^{[4] [5] [6]}

History

Pembrolizumab was approved by the US Food and Drug Administration in May 2017.^[7]

Larotrectinib was approved by the FDA in November, 2018.

Selpercatinib (LOXO-292) received priority review in September 2018 and was approved for medical use in the United States in May 2020.^{[8] [9]}

Entrectinib was approved for medical use in the United States in August 2019,^{[10] [11]} in Australia in May 2020,^[12] and in the European Union in July 2020.^[13]

Pralsetinib was approved for medical use in the United States in September 2020.^{[14] [15]}

Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. ^[16]

Tissue-agnostic cancer drugs that are under development include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies.

Notes and References

1. News: Bacon. John. 28 November 2018. FDA approves new drug reflecting cutting-edge, 'tissue-agnostic' effort to beat cancer. USA Today. 3 December 2018.
2. Garber. Ken. 16 June 2017. In a major shift, cancer drugs go 'tissue-agnostic'. Science. 356. 6343. 1111–1112. 10.1126/science.356.6343.1111. 28619894.
3. Garber. Ken. 16 June 2017. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nature. 17. 4. 227–229. 10.1038/nrd.2018.6. 29520093. 4417987 .
4. 10.1038/d41586-020-02679-6. The future of tissue-agnostic drugs . 2020 . Photopoulos . Julianna . Nature . 585 . 7826 . S16–S18 . 2020Natur.585S..16P . 221884179 .
5. 10.1016/j.trecan.2020.08.009. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm . 2021 . Adashek . Jacob J. . Subbiah . Vivek . Kurzrock . Razelle . Trends in Cancer . 7 . 1 . 15–28 . 33008795 . 222161382 . free .
6. News: Dun. Lauren. 27 Nov 2018. FDA approves a new cancer drug targeted to genetic mutation, not cancer type. NBC. 17 Dec 2018.
7. Web site: New Gene Targeting Cancer Drugs And Other Advances in Cancer Medicine – NextBigFuture.com. Wang. Brian. June 19, 2019. www.nextbigfuture.com. en-US. 2019-06-19.
8. FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion . U.S. Food and Drug Administration (FDA) . 8 May 2020 . 2022-05-04.
9. Web site: Retevmo: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 2022-05-04.
10. FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor . U.S. Food and Drug Administration (FDA) . 15 August 2019 . https://web.archive.org/web/20190914141848/https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor . 14 September 2019 . live . 23 November 2019.
11. Web site: Drug Approval Package: Rozlytrek . U.S. Food and Drug Administration (FDA) . 16 September 2019 . 23 November 2019.
12. Web site: Rozlytrek Australian prescription medicine decision summary . Therapeutic Goods Administration (TGA) . 25 May 2020 . 16 August 2020.
13. Web site: Rozlytrek EPAR . European Medicines Agency (EMA) . 26 May 2020 . 11 September 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
14. Web site: FDA approves pralsetinib for lung cancer with RET gene fusions . U.S. Food and Drug Administration (FDA) . 4 September 2020 . 2022-05-04.
15. Markham A . Pralsetinib: First Approval . Drugs . 80 . 17 . 1865–1870 . November 2020 . 33136236 . 10.1007/s40265-020-01427-4 . 226223522 .
16. Web site: FDA approves dabrafenib–trametinib for BRAF-positive cancers - NCI . 21 July 2022 .